RT Journal
A1 Abramson AL, Waner M, Brandsma J
T1 THe clinical treatment of laryngeal papillomas with hematoporphyrin therapy
JF Archives of Otolaryngology–Head & Neck Surgery
JO Archives of Otolaryngology–Head & Neck Surgery
YR 1988
FD July 1
VO 114
IS 7
SP 795
OP 800
DO 10.1001/archotol.1988.01860190099033
UL http://dx.doi.org/10.1001/archotol.1988.01860190099033
AB • Photodynamic activation of hematoporphyrin derivative was originally developed for the treatment of cancer. This article demonstrates that it may also be an effective therapy for papillomavirus infections of the larynx. Seventy-two hours prior to surgery, hematoporphyrin derivative (6 mg/kg) was given intravenously to two patients with the adultonset form of this disease. Three days later, endoscopic surgery was performed and 32 J cm2 was delivered to the endolarynx via an argon pump dye laser with a red light output of 630 nm. No significant complications such as swelling or hemorrhage occurred. At follow-up (13 months) there has been no recurrence of the laryngeal papilloma in either of these patients. The surgical technique, molecular biology, and clinical implications of this work to control laryngeal papillomatosis are described.(Arch Otolaryngol Head Neck Surg 1988;114:795-800)